Sarah Boyce insider trades: Atrium Therapeutics (RNA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sarah reports to the SEC
and 2 more companies
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | RNA | ↓ Sell10b5-1 | 14,387 | $72.45 | $1.0M | Direct | Jan 23, 2026 (2d) |
| Sep 5, 2025 | RNA | ↓ Sell | 50,000 | $49.95 | $2.5M | Direct | Sep 5, 2025 (0d) |
| Aug 28, 2025 | RNA | ↓ Sell | 25,000 | $49.39 | $1.2M | Direct | Aug 29, 2025 (1d) |
| Mar 20, 2025 | RNA | ↓ Sell10b5-1 | 31,540 | $31.06 | $980K | Direct | Mar 21, 2025 (1d) |
| Jan 21, 2025 | RNA | ↓ Sell10b5-1 | 10,397 | $28.59 | $297K | Direct | Jan 23, 2025 (2d) |
| Dec 18, 2024 | RNA | ↓ Sell10b5-1 | 31,855 | $32.66 | $1.0M | Direct | Dec 19, 2024 (1d) |
| Sep 23, 2024 | RNA | ↓ Sell10b5-1 | 32,880 | $44.00 | $1.4M | Direct | Sep 23, 2024 (0d) |
| Aug 6, 2024 | RNA | ↓ Sell | 28,000 | $43.35 | $1.2M | Direct | Aug 7, 2024 (1d) |
| Jul 9, 2024 | RNA | ↓ Sell | 28,000 | $39.93 | $1.1M | Direct | Jul 11, 2024 (2d) |
| Jun 18, 2024 | RNA | ↓ Sell10b5-1 | 32,074 | $39.13 | $1.3M | Direct | Jun 20, 2024 (2d) |
| Jun 14, 2024 | RNA | ↓ Sell | 300,000 | $38.63 | $11.6M | Direct | Jun 14, 2024 (0d) |
| Jun 4, 2024 | RNA | ↓ Sell | 28,000 | $27.42 | $768K | Direct | Jun 5, 2024 (1d) |
| May 7, 2024 | RNA | ↓ Sell | 28,000 | $25.54 | $715K | Direct | May 7, 2024 (0d) |
| Apr 2, 2024 | RNA | ↓ Sell | 28,000 | $26.25 | $735K | Direct | Apr 3, 2024 (1d) |
| Mar 12, 2024 | RNA | ↓ Sell | 112,000 | $21.70 | $2.4M | Direct | Mar 12, 2024 (0d) |
| Mar 1, 2024 | RNA | ↓ Sell | 84,000 | $20.13 | $1.7M | Direct | Mar 5, 2024 (4d) |
| Jan 22, 2024 | RNA | ↓ Sell10b5-1 | 5,092 | $10.13 | $52K | Direct | Jan 23, 2024 (1d) |
| Feb 3, 2023 | RNA | ↓ Sell | 50,000 | $24.35 | $1.2M | Direct | Feb 3, 2023 (0d) |
| Nov 10, 2022 | OABI | ↑ Buy | 36,000 | $2.82 | $101K | By spouse | Nov 14, 2022 (4d) |
| Aug 25, 2022 | RNA | ↓ Sell | 49,900 | $22.88 | $1.1M | Direct | Aug 26, 2022 (1d) |
| Aug 15, 2022 | RNA | ↓ Sell | 100 | $22.47 | $2K | Direct | Aug 17, 2022 (2d) |
| Mar 1, 2021 | BLI | ↓ Sell | 10,000 | $61.13 | $611K | Direct | Mar 3, 2021 (2d) |
| Jul 15, 2019 | AKCA | ↓ Sell | 1,819 | $23.52 | $43K | Direct | Jul 17, 2019 (2d) |
| Jan 16, 2018 | IONS | ↓ Sell | 2,196 | $51.76 | $114K | Direct | Jan 17, 2018 (1d) |
| Jan 17, 2017 | IONS | ↓ Sell | 1,361 | $46.29 | $63K | Direct | Jan 18, 2017 (1d) |
| Jan 19, 2016 | IONS | ↓ Sell | 872 | $41.46 | $36K | Direct | Jan 19, 2016 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RNA insiders
Open-market trades in the last 12 months
About Sarah Boyce's insider trades
Sarah Boyce is an insider at Atrium Therapeutics (RNA). Since Jan 19, 2016, Sarah has reported 1 open-market purchase worth $101K and 25 sales worth $33.3M on SEC Form 4. In the last 12 months: 1 sale ($1.0M).
7 sales (18% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (32 filings), option exercises (18 filings), other transactions (5 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.